Screener
PBE vs IDNA
Invesco Biotechnology & Genome ETF vs iShares Genomics Immunology and Healthcare ETF
Key differences
- IDNA costs 0.11% less per year.
- Over the last 3 years, PBE has delivered higher annualized returns.
- PBE has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| PBE | IDNA | |
|---|---|---|
| Annual cost (TER) | 0.58% | 0.47% |
| Fund size (AUM) | $247M | $160M |
| Since | 2005 | 2019 |
| Dividend yield | 1.09% | 1.05% |
| Asset class | equity | equity |
| Region | north america | — |
| Strategy | index tracking | index tracking |
| CAGR 1Y | +34.1% | +49.2% |
| CAGR 3Y | +10.3% | +8.0% |
| CAGR 5Y | +3.3% | -7.5% |
| Sharpe 3Y | 0.41 | 0.29 |
| Volatility 1Y | 18.63% | 24.43% |
| Max drawdown | -37.84% | -68.26% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to PBE and IDNA
Explore further